An interview with Dov Gertz, CEO and Co-founder at Converge Bio and Shahar Tzafrir, Managing Partner at TLV Partners on Generative AI for Drug Discovery and Development.

From discovering novel CRISPR systems using machine learning to building a generative lab for drug discovery.

Dov Gertz,, sat down with Shahar Tzafrir to talk about his journey, the inflection point we are seeing in AI and biology, and what it really takes to turn AI from promise into real impact.

They cover:
• Why AI in biology is shifting from models to systems
• How transformers, data scale and compute are reshaping drug discovery
• What a “generative lab” alongside traditional wet labs really means
• And what strong founder-investor partnerships look like in practice

This interview comes right after Converge Bio's PR announcement on raising $25M in Series A, announced on January 13, 2026.